Eli Lilly’s COVID-19 Drug Combination

by | Sep 20, 2021 | Compliance, Consulting Group, Coronavirus, COVID-19, FDA, Pharma, Pharmaceuticals


‌ 

At the beginning of the pandemic in 2020, Eli Lilly, a pharmaceutical company, joined forces with Junish Bioscience, a Chinese biopharmaceutical company, and AbCellera, a Canadian biotechnology organization, to develop two COVID-19 antibody drugs.

Eli Lilly succeeded and received FDA clearance for both antibody drugs. The first drug that was cleared by the FDA was bamlanivimab, a single antibody drug. The second drug combined bamlanivimab with etesevimab. The second FDA-cleared antibody drug was developed to be more effective and efficient at targeting mutating viruses, like the delta variant of COVID-19.

Four months after clearance from the FDA, in late June, the organizations were told to stop production on both drugs as the spread of the variants, like the beta, delta, and gamma variants, were not something the antibody drugs could neutralize. About 96% of US COVID cases right now are due to a variant, specifically the delta variant. US officials claimed that the halt in production was due to a lack of effectiveness against variants.

The antibody drug is now being used in states where the gamma and beta variants are not as prevalent. The FDA revised Eli Lilly’s antibody drug and mentioned that the drug will not be used in states where the gamma or beta variant is 5% or greater.

The 22 states that meet the 5% rule imposed by the FDA include: Connecticut, Colorado, Indiana, Illinois, Kansas, Maine, Iowa, New Hampshire, Massachusetts, Minnesota, Michigan, Montana, North Dakota, Minnesota, Missouri, Rhode Island, Ohio, Utah, Vermont, Wyoming, and Wisconsin. 1

To learn more about quality, regulatory, or compliance, EMMA International’s team of experts has you covered. Contact us at 248-987-4497, or email info@emmainternational.com today!

1FDA restarts distribution of Lilly’s COVID-19 drug in 22 states. (n.d.). MedTech Dive. Retrieved September 13, 2021, from https://www.medtechdive.com/news/lilly-covid-antibody-fda-restart-distribution/605883/

Abby McVay

Abby McVay

Research Analyst- Ms. McVay is EMMA International’s Research Analyst. She has experience in technical writing and clinical trials in many life science industries. She has experience with many different elements of quality and regulatory compliance. Ms. McVay holds a Bachelor of Science in Psychology from Manchester University as well as a Master of Science in Industrial and Organizational Psychology from Angelo State University.

More Resources

Pattern Recognition as a Quality Superpower

Pattern Recognition as a Quality Superpower

There are always new ways and reasons to apply pattern recognition to quality improvement. Better ensuring patient outcomes in health care facilities and improving accuracy for medical diagnoses are two such frontiers.
Record Control for a Regulated World

Record Control for a Regulated World

In a regulated industry, the prevailing posture of regulatory representatives, in my experience, has been “Show me proof.” In fact, the philosophy I’ve heard repeated by regulators is “If it wasn’t documented, it didn’t happen.”
EU MDR SSCP’s: The Importance of Readability

EU MDR SSCP’s: The Importance of Readability

Among many of the new requirements that EU MDR has introduced, the Summary of Safety and Clinical Performance (SSCP) is certainly one of the more confusing ones for many firms. SSCP’s are required for implantable and Class III devices under EU MDR and is intended to be a public document summarizing important safety and clinical performance information about the device.

Ready to learn more about working with us?

Pin It on Pinterest

Share This